First Test to ID Candida auris Gets FDA Approval
The Bruker Maldi system is already cleared for use in identifying 333 species or species groups, including 424 bacteria and yeast species.
Fungal Infections
Large Drop Seen in Infection-Related Post-Transplant Deaths
Infectious causes of death and mortality rates for infections for 2 time periods – 1990 to 1999 and 2000 to 2012 – among 3,249 adult recipients of a first kidney transplant were assessed during the study period.
FDA Approves the Use of Luzu Cream in Younger Patients
Luzu, an azole antifungal, is indicated for the topical treatment of interdigital tinea pedis, tinea cruris, and tinea corporis caused by the organisms Trichophyton rubrum and Epidermophyton floccosum.
FDA: New Tool to Help Clinicians Make Appropriate Antibiotic Choices
New website streamlines how FDA updates information used to help health care providers choose an appropriate treatment for a patient’s infection.
Perrigo Approved for Generic Mycolog II Cream
Triamcinolone acetonide is mainly effective because of its anti-inflammatory, antipruritic and vasoconstrictive actions.
Antifungal Tablets to Be Discontinued
Novartis Pharmaceuticals has made a business decision to permanently discontinue the product Lamisil Tablets 250mg.
Test Helps Clinicians Select Appropriate Tx for Suspected Wound Infections
Using a simple swab from the infection site, DxWound uses a special transport buffer that preserves the wound microbiome during transit.
FDA Fast Tracks New Oral Antifungal to Treat Valley Fever
VT-1598, an oral fungal CYP51 inhibitor, has shown high potency against pathogens such as molds, yeasts, and multi-drug resistant fungal pathogens (eg, Candida auris).
Addition of Antifungal to Cancer Tx Leads to Nephrotic Syndrome
Case report of patient with relapsed Hodgkin’s lymphoma treated with everolimus for five years
Therapies Compared for Treating Deadly Fungal Infection in HIV Patients
Compared with itraconazole, amphotericin treatment correlated with significantly faster clinical resolution and fungal clearance and with significantly lower rates of relapse and immune reconstitution inflammatory syndrome.
